Copy of Company2019-08-28T11:17:20+08:00

About Us

SINOMED is a global company engaged in patient-focused medical innovations for interventional medicine. We offer pioneering solutions and high-quality products for treating coronary and neurovascular disease. We strive to combine the ingenuity of people with the power of technology to achieve new victories against cardiovascular disease.

About Us        Our Values        Facts and Figures        SINOMED group locations        Milestones        Honors & Grants        Careers

SINOMED was founded in 2007 by Dr. Jianhua Sun as a startup company searching for a way to improve the common coronary stent. Today, the company is a leader in the Chinese coronary stent market with its headquarters located in Tianjin, China, with a 2,000 m² class 10,000 cleanroom for manufacturing, quality control and development. Since its humble beginnings, SINOMED has worked closely with industry thought-leaders expanding its product offering to include a portfolio of coronary stents and balloons, as well as neurovascular products.

Our mission is to become a global leader in medical devices, focusing on supporting healthcare professions in their daily efforts to improve the lives of patients. We do this by continuing to evolve our technologies, focus on quality in everything we do and strive to secure global access to our devices. At SINOMED, we are creating innovations for health.

Our mission is to become a global leader in medical devices, focusing on supporting healthcare professions in their daily efforts to improve the lives of patients. We do this by continuing to evolve our technologies, focus on quality in everything we do and strive to secure global access to our devices. At SINOMED, we are creating innovations for health.

IN THE EYES OF THE EXPERTS

Dr. Renu Virmani

M.D., Pathologist,
President of CVPath,
Leader of BuMA’s rabbit
and swine animal study.

“SINOMED is not a me-too company. It brought innovation to China.”

Dr. Yong Huo

M.D., FACC, president of
Chinese Society of
Cardiology, PI of BuMA’s
PANDA II clinical trial.

“Trying to solve the main problem of DES – the late or very late in-stent thrombosis – by the achievement on endothelialization, BuMA™ could be a milestone on the way of the development and innovation of DES not only in China, but in the world. ”

Christophe Bureau

Ph.D, Founder of
AlchiMedics, Inventor of
eG™ technology.

“With the safest coating technology available for drug eluting stent, we solved the legendary issue of late thrombosis. It’s my honor to work with SINOMED driving innovation from research to product development.”